- LloydsPharmacy has signed a sales and distribution agreement for VIRALEZE™ with Australian biopharmaceutical company Starpharma
- The UK is the first country in Europe to launch VIRALEZE™ and it will initially be available exclusively at LloydsPharmacy, one of the largest pharmacy chains in the UK with around 1,400 community-based pharmacies
- VIRALEZE™ is a broad spectrum antiviral nasal spray that contains astodrimer sodium (SPL7013) which is virucidal, irreversibly inactivating >99.9% of coronavirus/SARS-CoV-2 within one minute
- SPL7013 has been shown to be highly active against multiple strains of SARS-CoV-2 as well as a broad spectrum of other respiratory viruses
- The bottle, which retails for £15, will deliver approximately 80 sprays
An easy-to-use antiviral nasal spray that inactivates the coronavirus that causes COVID-19, as well as other important respiratory viruses, is now available for the first time to consumers in the UK, exclusively online at www.LloydsPharmacy.com and instore from 21st April.
VIRALEZE™ antiviral nasal spray was developed by Starpharma based on an already marketed active and is now registered for sale in the UK and Europe. It offers another layer of protection in addition to vaccines, masks, and physical distancing, helping to reduce exposure to respiratory viruses.
Dr Jackie Fairley, CEO of Starpharma, commented: “We are excited that VIRALEZE™ is now available in the second largest pharmacy chain in the UK. The LloydsPharmacy team shares Starpharma’s enthusiasm and commitment to bring VIRALEZE™ antiviral nasal spray to UK consumers as they emerge from their latest lockdown. LloydsPharmacy represents an ideal partner for this product.”
“VIRALEZE™ was developed, manufactured and registered by Starpharma ahead of its original schedule, and it is particularly rewarding to have it available in such a large and sophisticated market”, added Dr Fairley.
VIRALEZE™ is a broad spectrum antiviral nasal spray that contains astodrimer sodium (SPL7013) which is virucidal, irreversibly inactivating >99.9% of coronavirus/SARS-CoV-2 within one minute, as shown in laboratory studies conducted at the renown Scripps Research Institute in the US. SPL7013 has also demonstrated potent antiviral activity against multiple strains of SARS-CoV-2.
The antiviral active (SPL7013) in VIRALEZE™ irreversibly blocks coronavirus SARS-CoV-2 ‘spike’ proteins from binding to nasal mucosal cells required for infection. VIRALEZE™ has a number of unique advantages, including its virucidal action, its rapid onset (inactivates >99.9% SARS-CoV-2 within one minute) and its ability to inactivate virus either before or after exposure, and provides a physical barrier to respiratory viruses in the nasal cavity.
John Acland, Head of e-Commerce and Category Management at LloydsPharmacy, commented: “We are excited to have secured exclusive rights to VIRALEZE for the UK. It is a highly innovative product with compelling customer benefits and is well supported by an impressive body of quality science and research. We hope VIRALEZE™ will bring LloydsPharmacy customers added peace of mind and protection as we enter the next chapter of the pandemic and re-emerge back into work, school and social settings.”
Starpharma has conducted multiple antiviral studies in internationally recognised specialist virology laboratories located in Australia, the US and Europe. The SARS-CoV-2 testing was conducted from March 2020 and is ongoing as more strains emerge.
Dr George Kinghorn, Infectious Disease Adviser and former Clinical Director of the Sheffield Teaching Hospitals NHS Foundation Trust, commented: “Given that multiple studies have reported that the nasal cavity appears to be the most important route of initial coronavirus infection, VIRALEZE™ should be a very useful tool in addition to other prevention strategies such as vaccines, masks and social distancing.”
“Recent experience suggests that viral pandemics will occur again, so the availability of broad-spectrum antiviral agents, like VIRALEZE™, could prove extremely useful,” added Dr Kinghorn.